Literature DB >> 27815918

Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie.

Clémence Béchade1,2, Olivier Dejardin3,4, Simona Bara5,6, Véronique Bouvier3,4,7, Anne-Valérie Guizard4,8, Rémy De Mil3,4, Xavier Troussard3,5,9, Thierry Lobbedez3,4, Guy Launoy3,4.   

Abstract

Aims To estimate the incidence of chronic dialysis in patients with a history of cancer and assess how renal replacement therapy is initiated in this population. Methods We merged data from cancer registries and hospital databases in one French region to identify patients with an incident cancer between 2001 and 2008 who started chronic dialysis. Results Mean participation time was 3.4 ± 2.7 years. Males comprised 58.5 % of participants. During the study period, 74 chronic dialysis treatments were initiated. Chronic interstitial nephritis was the leading cause of end-stage renal disease (21.6 %), and 46.6 % of dialysis initiation cases were unplanned. The incidence rate of chronic dialysis initiation in the population of incident cancer patients was 370 per million population/year (74 events/199,809 person-years). After age-adjustment, the standardized incidence ratio was 1.26, 95 % confidence interval 0.98-1.57, p = 0.55. Conclusion Cancer patients are known to be at risk of chronic kidney disease. However, the standardized incidence ratio of chronic dialysis initiation did not differ significantly between cancer patients and the general population. Further studies should be performed to identify the barriers to starting renal replacement therapy in cancer patients.

Entities:  

Keywords:  Cancer; Dialysis; Incidence; Renal replacement therapy

Mesh:

Year:  2016        PMID: 27815918     DOI: 10.1007/s40620-016-0356-8

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  14 in total

1.  [Generating person-years and calculating SMR using SAS: a simple program for exact calculations].

Authors:  J-L Marchand
Journal:  Rev Epidemiol Sante Publique       Date:  2010-10-12       Impact factor: 1.019

2.  Glomerular disease related to anti-VEGF therapy.

Authors:  M Barry Stokes; Maria C Erazo; Vivette D D'Agati
Journal:  Kidney Int       Date:  2008-06-11       Impact factor: 10.612

3.  Conservative care in Europe--nephrologists' experience with the decision not to start renal replacement therapy.

Authors:  Moniek W M van de Luijtgaarden; Marlies Noordzij; Wim van Biesen; Cecile Couchoud; Giovanni Cancarini; Willem-Jan W Bos; Friedo W Dekker; Jose L Gorriz; Christos Iatrou; Christoph Wanner; Patrik Finne; Olivera Stojceva-Taneva; Svjetlana Cala; Vianda S Stel; Charles Tomson; Kitty J Jager
Journal:  Nephrol Dial Transplant       Date:  2013-09-07       Impact factor: 5.992

Review 4.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.

Authors:  N E Breslow; N E Day
Journal:  IARC Sci Publ       Date:  1987

5.  Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis Initiation.

Authors:  Mae Thamer; James S Kaufman; Yi Zhang; Qian Zhang; Dennis J Cotter; Heejung Bang
Journal:  Am J Kidney Dis       Date:  2015-06-26       Impact factor: 8.860

6.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

Authors:  Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia
Journal:  Lancet Oncol       Date:  2013-12-05       Impact factor: 41.316

7.  Patient referral is influenced by dialysis centre structure in the Diamant Alpin Dialysis cohort study.

Authors:  Jean-Pierre Wauters; Jean-Luc Bosson; Giacomo Forneris; Cécile Turc-Baron; Dela Golshayan; Giuseppe Paternoster; Guido Martina; Jean-Marc Hurot; Beat von Albertini; Michel Forêt; Daniel Cordonnier; Giuseppe Piccoli
Journal:  Nephrol Dial Transplant       Date:  2004-07-13       Impact factor: 5.992

8.  Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.

Authors:  Vincent Launay-Vacher; Stéphane Oudard; Nicolas Janus; Joseph Gligorov; Xavier Pourrat; Olivier Rixe; Jean-François Morere; Philippe Beuzeboc; Gilbert Deray
Journal:  Cancer       Date:  2007-09-15       Impact factor: 6.860

9.  Cancer and renal insufficiency results of the BIRMA study.

Authors:  N Janus; V Launay-Vacher; E Byloos; J-P Machiels; L Duck; J Kerger; W Wynendaele; J-L Canon; W Lybaert; J Nortier; G Deray; H Wildiers
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

10.  Development and validation of a predictive mortality risk score from a European hemodialysis cohort.

Authors:  Jürgen Floege; Iain A Gillespie; Florian Kronenberg; Stefan D Anker; Ioanna Gioni; Sharon Richards; Ronald L Pisoni; Bruce M Robinson; Daniele Marcelli; Marc Froissart; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

View more
  2 in total

1.  Risk Factors for Unplanned Dialysis Initiation: A Systematic Review of the Literature.

Authors:  Rana Hassan; Ayub Akbari; Pierre A Brown; Swapnil Hiremath; K Scott Brimble; Amber O Molnar
Journal:  Can J Kidney Health Dis       Date:  2019-03-13

Review 2.  Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?

Authors:  Jolanta Małyszko; Leszek Kozlowski; Klaudia Kozłowska; Maciej Małyszko; Jacek Małyszko
Journal:  Oncotarget       Date:  2017-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.